Literature DB >> 19368784

Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes.

Araceli E Santiago1, Leah E Cole, Augusto Franco, Stefanie N Vogel, Myron M Levine, Eileen M Barry.   

Abstract

Francisella tularensis, the etiologic agent of tularemia, can cause severe and fatal infection after inhalation of as few as 10 -- 100CFU. F. tularensis is a potential bioterrorism agent and, therefore, a priority for countermeasure development. Vaccination with the live vaccine strain (LVS), developed from a Type B strain, confers partial protection against aerosal exposure to the more virulent Type A strains and provides proof of principle that a live attenuated vaccine strain may be efficacious. However LVS suffers from several notable drawbacks that have prevented its licensure and widespread use. To address the specific deficiencies that render LVS a sub-optimal tularemia vaccine, we engineered F. tularensis LVS strains with targeted deletions in the guaA or guaB genes that encode critical enzymes in the guanine nucleotide biosynthetic pathway. F. tularensis LVSDeltaguaA and LVSDeltaguaB mutants were guanine auxotrophs and were highly attenuated in a mouse model of infection. While the mutants failed to replicate in macrophages, a robust proinflammatory cytokine response, equivalent to that of the parental LVS, was elicited. Mice vaccinated with a single dose of the F. tularensis LVSDeltaguaA or LVSDeltaguaB mutant were fully protected against subsequent lethal challenge with the LVS parental strain. These findings suggest the specific deletion of these target genes could generate a safe and efficacious live attenuated vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368784      PMCID: PMC2716139          DOI: 10.1016/j.vaccine.2009.02.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

Review 1.  Francisella tularensis genomics and proteomics.

Authors:  Richard W Titball; Joseph F Petrosino
Journal:  Ann N Y Acad Sci       Date:  2007-04-13       Impact factor: 5.691

Review 2.  Uptake and intracellular fate of Francisella tularensis in human macrophages.

Authors:  Daniel L Clemens; Marcus A Horwitz
Journal:  Ann N Y Acad Sci       Date:  2007-04-13       Impact factor: 5.691

3.  Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Authors:  Karen L Kotloff; Marcela F Pasetti; Eileen M Barry; James P Nataro; Steven S Wasserman; Marcelo B Sztein; William D Picking; Myron M Levine
Journal:  J Infect Dis       Date:  2004-10-19       Impact factor: 5.226

4.  Characterization of the nucleotide sequence of the groE operon encoding heat shock proteins chaperone-60 and -10 of Francisella tularensis and determination of the T-cell response to the proteins in individuals vaccinated with F. tularensis.

Authors:  M Ericsson; I Golovliov; G Sandström; A Tärnvik; A Sjöstedt
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 5.  Vaccination strategies for Francisella tularensis.

Authors:  Karen E Isherwood; Richard W Titball; D Huw Davies; Phillip L Felgner; W John W Morrow
Journal:  Adv Drug Deliv Rev       Date:  2005-06-17       Impact factor: 15.470

6.  Construction and characterization of a highly efficient Francisella shuttle plasmid.

Authors:  Tamara M Maier; Andrea Havig; Monika Casey; Francis E Nano; Dara W Frank; Thomas C Zahrt
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

7.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

Review 8.  Francisella tularensis: activation of the inflammasome.

Authors:  David S Weiss; Thomas Henry; Denise M Monack
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

9.  Francisella tularensis selectively induces proinflammatory changes in endothelial cells.

Authors:  Colin A Forestal; Jorge L Benach; Chateen Carbonara; Jaime K Italo; Tracy J Lisinski; Martha B Furie
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

10.  Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Authors:  Karen L Kotloff; Jakub K Simon; Marcela F Pasetti; Marcelo B Sztein; Stacey L Wooden; Sofie Livio; James P Nataro; William C Blackwelder; Eileen M Barry; Wendy Picking; Myron M Levine
Journal:  Hum Vaccin       Date:  2007-07-15
View more
  29 in total

Review 1.  The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors.

Authors:  L Hedstrom; G Liechti; J B Goldberg; D R Gollapalli
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Mutational Analysis of the Chlamydia muridarum Plasticity Zone.

Authors:  Krithika Rajaram; Amanda M Giebel; Evelyn Toh; Shuai Hu; Jasmine H Newman; Sandra G Morrison; Laszlo Kari; Richard P Morrison; David E Nelson
Journal:  Infect Immun       Date:  2015-05-04       Impact factor: 3.441

3.  Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling.

Authors:  Leah E Cole; Michelle H W Laird; Anna Seekatz; Araceli Santiago; Zhaozhao Jiang; Eileen Barry; Kari Ann Shirey; Katherine A Fitzgerald; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

4.  De Novo Guanine Biosynthesis but Not the Riboswitch-Regulated Purine Salvage Pathway Is Required for Staphylococcus aureus Infection In Vivo.

Authors:  Eric M Kofoed; Donghong Yan; Anand K Katakam; Mike Reichelt; Baiwei Lin; Janice Kim; Summer Park; Shailesh V Date; Ian R Monk; Min Xu; Cary D Austin; Till Maurer; Man-Wah Tan
Journal:  J Bacteriol       Date:  2016-06-27       Impact factor: 3.490

5.  Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.

Authors:  Leah E Cole; Barbara J Mann; Kari Ann Shirey; Katharina Richard; Yang Yang; Patricia J Gearhart; Kirsty L Chesko; Rose M Viscardi; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2011-07-12       Impact factor: 4.962

6.  Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis.

Authors:  Suresh Kumar Gorla; Yan Zhang; Meaghan M Rabideau; Aiping Qin; Shibin Chacko; Amanda L House; Corey R Johnson; Kavitha Mandapati; Hannah M Bernstein; Elizabeth S McKenney; Helena Boshoff; Minjia Zhang; Ian J Glomski; Joanna B Goldberg; Gregory D Cuny; Barbara J Mann; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

7.  Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Authors:  Douglas S Reed; Le'kneitah P Smith; Kelly Stefano Cole; Araceli E Santiago; Barbara J Mann; Eileen M Barry
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

Review 8.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

Review 9.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 10.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.